Log In

New? Register Here

Keryx Biopharmaceuticals

20th Floor, 750 Lexington Ave.
NEW YORK, NY 10022

  • Main Phone: (212) 531-5965
  • Fax Number: (212) 531-5961
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Endorsements: None Provided
  • Announcements: 0


Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and survival. KRX-0401 is in Phase III clinical development for both refractory advanced colorectal cancer and relapsed / refractory multiple myeloma, and in Phase I and Phase II clinical development for other tumor types. It is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes.


Not provided at this time


Not provided at this time


There are no company announcements at this time.

Company's Strengths and Specialties

There is no information provided at this time.